Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.

Article  PubMed  PubMed Central  Google Scholar 

Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91–103.

Article  CAS  PubMed  Google Scholar 

Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, et al. Long-term outcomes from a randomized dose optimization study of chimeric Antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2862–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin Lymphoma. J Clin Oncol. 2020;38:3794–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378:449–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after chimeric Antigen receptor T-Cell therapy. N Engl J Med. 2016;375:2561–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of mesothelin-specific chimeric Antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155:29–32.

Article  CAS  PubMed  Google Scholar 

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) -Specific chimeric Antigen receptor-modified T cells for the Immunotherapy of HER2-Positive sarcoma. J Clin Oncol. 2015;33:1688–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724–34.

Article  CAS  PubMed  Google Scholar 

Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531–50.

Article  CAS  PubMed  Google Scholar 

Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–85.

CAS  PubMed  PubMed Central  Google Scholar 

Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775–90.

Article  PubMed  Google Scholar 

Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34–48.

Article  CAS  PubMed  Google Scholar 

Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin Cytom. 2020;98:299–327.

Article  PubMed  Google Scholar 

Sarikonda G, Pahuja A, Kalfoglou C, Burns K, Nguyen K, Ch’en IL, et al. Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges. Cytometry B Clin Cytom. 2021;100:72–8.

Article  CAS  PubMed  Google Scholar 

Kharchenko PV. The triumphs and limitations of computational methods for scRNA-seq. Nat Methods. 2021;18:723–32.

Article  CAS  PubMed  Google Scholar 

Erfanian N, Derakhshani A, Nasseri S, Fereidouni M, Baradaran B, Jalili Tabrizi N, et al. Immunotherapy of cancer in single-cell RNA sequencing era: a precision medicine perspective. Biomed Pharmacother. 2022;146:112558.

Article  CAS  PubMed  Google Scholar 

Hwang B, Lee JH, Bang D. Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp Mol Med. 2018;50:1–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18:35–45.

Article  CAS  PubMed  Google Scholar 

Xu X, Hua X, Mo H, Hu S, Song J. Single-cell RNA sequencing to identify cellular heterogeneity and targets in cardiovascular diseases: from bench to bedside. Basic Res Cardiol. 2023;118:7.

Article  PubMed  Google Scholar 

Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408–14.

Article  CAS  PubMed  Google Scholar 

Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:379–93.

Article  PubMed  PubMed Central  Google Scholar 

Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18:715–27.

Article  CAS  PubMed  Google Scholar 

Meyran D, Terry RL, Zhu JJ, Haber M, Ziegler DS, Ekert PG, et al. Early-phenotype CAR-T cells for the treatment of pediatric cancers. Ann Oncol. 2021;32:1366–80.

Article  CAS  PubMed  Google Scholar 

Liu Y, Sperling AS, Smith EL, Mooney DJ. Optimizing the manufacturing and antitumour response of CAR T therapy. Nat Rev Bioeng. 2023:1–15.

Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21:194.

Article  PubMed  PubMed Central  Google Scholar 

Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8 + composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–38.

Article  PubMed  PubMed Central  Google Scholar 

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492–500.

Article  CAS  PubMed  Google Scholar 

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11:2186–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunoth

留言 (0)

沒有登入
gif